Five Prime Therapeutics gets bullish new coverage

|About: Five Prime Therapeutics, Inc. (FPRX)|By:, SA News Editor

Analysts are out with a bevy of upbeat coverage initiations for Five Prime Therapeutics (FPRX).

Jefferies: Buy, PT $20.

Wells Fargo: Outperform, PT $18.

Guggenheim: Buy, PT $20.

BMO: Outperform, PT $24.

Look for data from a Phase 1b trial of GSK-partnered FP-1039 (it's an FGF pathway inhibitor) late next year.